374 related articles for article (PubMed ID: 15848071)
1. Tailor-made antibody therapeutics.
Chowdhury PS; Wu H
Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
[TBL] [Abstract][Full Text] [Related]
2. Antibodies and genetically engineered related molecules: production and purification.
Roque AC; Lowe CR; Taipa MA
Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
[TBL] [Abstract][Full Text] [Related]
3. Engineered single chain antibody fragments for radioimmunotherapy.
Huhalov A; Chester KA
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):279-88. PubMed ID: 15640791
[TBL] [Abstract][Full Text] [Related]
4. Harnessing phage and ribosome display for antibody optimisation.
Dufner P; Jermutus L; Minter RR
Trends Biotechnol; 2006 Nov; 24(11):523-9. PubMed ID: 17000017
[TBL] [Abstract][Full Text] [Related]
5. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.
Weisser NE; Hall JC
Biotechnol Adv; 2009; 27(4):502-20. PubMed ID: 19374944
[TBL] [Abstract][Full Text] [Related]
6. Antibody engineering for the development of therapeutic antibodies.
Kim SJ; Park Y; Hong HJ
Mol Cells; 2005 Aug; 20(1):17-29. PubMed ID: 16258237
[TBL] [Abstract][Full Text] [Related]
7. Selection, design, and engineering of therapeutic antibodies.
Presta LG
J Allergy Clin Immunol; 2005 Oct; 116(4):731-6; quiz 737. PubMed ID: 16210043
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic antibody production technologies: molecules, applications, expression and purification.
Humphreys DP; Glover DJ
Curr Opin Drug Discov Devel; 2001 Mar; 4(2):172-85. PubMed ID: 11378956
[TBL] [Abstract][Full Text] [Related]
9. Antibody engineering: facing new challenges in cancer therapy.
Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
[TBL] [Abstract][Full Text] [Related]
10. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
Haurum JS
Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535
[TBL] [Abstract][Full Text] [Related]
11. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
Huang C
Curr Opin Biotechnol; 2009 Dec; 20(6):692-9. PubMed ID: 19889530
[TBL] [Abstract][Full Text] [Related]
12. Antibody therapeutics, antibody engineering, and the merits of protein stability.
Demarest SJ; Glaser SM
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
[TBL] [Abstract][Full Text] [Related]
13. Single-chain antibodies as new antithrombotic drugs.
Hagemeyer CE; Schwarz M; Peter K
Semin Thromb Hemost; 2007 Mar; 33(2):185-95. PubMed ID: 17340468
[TBL] [Abstract][Full Text] [Related]
14. Design of humanized antibodies: from anti-Tac to Zenapax.
Tsurushita N; Hinton PR; Kumar S
Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
[TBL] [Abstract][Full Text] [Related]
15. Antibody evolution beyond Nature.
Borrebaeck CA; Ohlin M
Nat Biotechnol; 2002 Dec; 20(12):1189-90. PubMed ID: 12454662
[No Abstract] [Full Text] [Related]
16. [Therapeutic antibodies and related products: choosing the right structure for success].
Beck A; Wagner-Rousset E; Wurch T; Corvaia N
Med Sci (Paris); 2009 Dec; 25(12):1024-32. PubMed ID: 20035674
[TBL] [Abstract][Full Text] [Related]
17. Development of humanized antibodies as cancer therapeutics.
Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
Siberil S; Dutertre CA; Boix C; Teillaud JL
Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
[TBL] [Abstract][Full Text] [Related]
19. [Progression and direction of humanized antibody research].
Lin Y; Yan XY
Sheng Wu Gong Cheng Xue Bao; 2004 Jan; 20(1):1-5. PubMed ID: 16108479
[TBL] [Abstract][Full Text] [Related]
20. The rapid discovery of engineered antibodies.
Wang M; He M
IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
